Reviews

User reviews

User Review - Flag as inappropriate

Cytokinetics Post Ispinesib; clinical trial data
(CYTK) 4.86: Company published ongoing I / II stage <a href="http://www.medchemexpress.com/product/Ispinesib.html">Ispinesib</a>; clinical trial
data, the first stage was found that the best response rate was three patients functional damage reduced by 30% or more in diameter, where a tumor appeared local reactions, three patients after four months or longer periods in stable condition. The most common side effects were neutropenia syndrome, accounting for 85%.
Medchemexpress Can provide the above product,its website:<a href="http://www.medchemexpress.com">www.medchemexpress.com</a>
<a href="http://www.medchemexpress.com/product/VX-745.html">VX-745</a>
<a href="http://www.medchemexpress.com/product/TAK-715.html">TAK-715</a>
<a href="http://www.medchemexpress.com/product/SB-239063.html">SB 239063</a>
<a href="http://www.medchemexpress.com/product/SD-06.html">SD-06</a>
<a href="http://www.medchemexpress.com/product/Vinorelbine.html">Vinorelbine</a>
<a href="http://www.medchemexpress.com/product/LY2228820.html">LY2228820</a>
<a href="http://www.medchemexpress.com/product/PD0325901.html">PD0325901</a>
<a href="http://www.medchemexpress.com/product/Trametinib.html">Trametinib</a>
<a href="http://www.medchemexpress.com/product/GSK1120212-DMSO-solvate.html">GSK1120212 DMSO solvate</a>
<a href="http://www.medchemexpress.com/product/PD98059.html">PD98059</a>
 

All reviews - 1
5 stars - 0
4 stars - 0
3 stars - 0
2 stars - 0
1 star - 0

All reviews - 1
Editorial reviews - 0